check_circleStudy Completed

CE in MRI: Liver

Primovist: DDI with OATP-Inhibitor

Trial purpose

Please see attached Study Results Summary below

Key Participants Requirements

Sex

N/A

Age

18 Years
  • -

  • -

Trial summary

Enrollment Goal
12
Trial Dates
May 2009 - July 2009
Phase
Phase 1
Could I Receive a placebo
N/A
Products
Eovist/Primovist (Gadoxetate disodium, BAY86-4873)
Accepts Healthy Volunteer
N/A

Where to participate

StatusInstitutionLocation
Completed
Bayer Schering Pharma AGBerlin, 13353, Germany

Trial design

Open-label, randomized, single-center, crossover study to evaluate the possible influence of erythromycin as a representative of an inhibitor of the organic anion transporting peptide on the hepatocyte uptake of Eovist/Primovist in liver MR imaging in healthy volunteers
Trial Type
Interventional
Intervention Type
N/A
Trial Purpose
N/A
Allocation
N/A
Blinding
N/A
Assignment
N/A
Trial Arms
N/A